Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02190916 · ClinicalTrials.gov registry record
Vasculitis Illness Perception (VIP) Study
A clinical trial of Giant Cell Arteritis and Microscopic Polyangiitis, sponsored by University of South Florida.
- Completed
- Registry status
- 707
- Enrollment target
- 1
- Study location
NCT02190916: Completed study of Giant Cell Arteritis and Microscopic Polyangiitis, sponsored by University of South Florida.
NCT02190916 is a study of Giant Cell Arteritis and Microscopic Polyangiitis that has completed, run by University of South Florida. The registered enrollment target is 707 participants, below the 949-participant average among 7 other Giant Cell Arteritis trials with a reported enrollment target (26% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02190916, a study of Giant Cell Arteritis and Microscopic Polyangiitis, has completed, sponsored by University of South Florida.
- COMPLETED
- Registry status
- 707 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to learn about how patients with vasculitis think about their illness and to assess to what extent patient perceptions of illness are associated with physical, mental, and social functioning
Primary Outcome
The outcome measure(s) will be evaluated based on the cross-sectional online questionnaire. The questionnaire is the only study procedure for this online patient contact registry protocol and will be the sole analysis tool for both the primary and secondary outcome measures.
Conditions Studied
Study Locations (1)
Florida
- University of South Florida Data Management Coordinating Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 707 participants |
| Start Date | 2011-10 |
| Est. Completion | 2013-10 |
What the finished NCT02190916 record still lists
NCT02190916 is an observational study that tracks outcomes without assigning an intervention. The registered 707 participants enrollment target is mid-sized for trials with a published cap, below the 949-participant average among 7 other Giant Cell Arteritis trials with a reported enrollment target (26% lower).
The record links to 9 conditions, with Giant Cell Arteritis appearing as the primary indexed condition, and to 0 interventions.
NCT02190916 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT02190916 about?
NCT02190916 is a clinical study titled "Vasculitis Illness Perception (VIP) Study". The purpose of this study is to learn about how patients with vasculitis think about their illness and to assess to what extent patient perceptions of illness are associated with physical, mental, and social functioning
What is the current status of trial NCT02190916?
This trial is currently completed. The enrollment target is 707 participants. The study started on 2011-10. Estimated completion is 2013-10.
What conditions does trial NCT02190916 study?
This clinical trial studies the following conditions: Giant Cell Arteritis, Microscopic Polyangiitis, Takayasu's Arteritis, Polyarteritis Nodosa, Churg-Strauss Syndrome.
Who is sponsoring clinical trial NCT02190916?
This trial is sponsored by University of South Florida, which has 252 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02190916 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Giant Cell Arteritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Vascular MRI Evaluation in Giant Cell Arteritis (VEGA)
RECRUITING
-
One-Time DNA Study for Vasculitis
RECRUITING
-
VCRC Tissue Repository
RECRUITING
-
Abatacept for the Treatment of Giant Cell Arteritis
RECRUITING · Phase 3
-
Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis
RECRUITING
-
Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06480383 · 705 participants · Phase 2
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
- NCT07067463 · 705 participants · Phase 3
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
- NCT06179160 · 710 participants · Phase 1
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- NCT06235697 · 710 participants · Phase 3
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia